The STOP NIDDM study published in 2002 has revealed the advantage of alpha glucosidase inhibitors in prevention of progress of potential diabetic patients into Type II diabetic patients in addition to controlling the risk of cardiovascular damage [8]. This evidence concerns the gene GAA and type 2 diabetes mellitus.